玻璃体内注射雷珠单抗治疗近视性脉络膜新生血管：年龄的作用
Treatment of myopic choroidal neovascularization with intravitreal ranibizumab injections: the role of age.
作者信息
Karagiannis Dimitrios, Kontadakis Georgios A, Kaprinis Konstantinos, Giarmoukakis Athanassios, Georgalas Ilias, Parikakis Efstratios A, Tsilimbaris Miltiadis K
机构信息
Ophthalmiatreio Eye Hospital of Athens, Athens, Greece.
Department of Ophthalmology, University Hospital of Heraklion, University of Crete, Heraklio, Greece.
出版信息
Clin Ophthalmol. 2017 Jun 22;11:1197-1201. doi: 10.2147/OPTH.S135174. eCollection 2017.
PURPOSE
The aim of this study was to explore the role of age as a prognostic factor for the outcome of myopic choroidal neovascularization (CNV) treatment with intravitreal ranibizumab injections.
METHODS
A retrospective review of charts of patients treated with intravitreal injections of ranibizumab for the treatment of myopic CNV was done. Patients with other ophthalmic disease were excluded. Patients were followed for at least 2 years. The correlation between age and the change in visual acuity and the number of injections during treatment was investigated.
RESULTS
Age of the patients was significantly correlated with the number of injections that the patients received (Pearson's =0.585, =0.005). Also, it was significantly correlated with improvement in corrected distance visual acuity, defined as the difference between final and initial LogMAR corrected distance visual acuity (Pearson's =0.614, =0.003).
CONCLUSION
Age significantly affects the visual outcome of myopic CNV treatment with ranibizumab. Younger patients in our study needed fewer intravitreal injections and achieved a more significant improvement in vision.
目的
本研究旨在探讨年龄作为玻璃体内注射雷珠单抗治疗近视性脉络膜新生血管（CNV）预后因素的作用。
方法
对接受玻璃体内注射雷珠单抗治疗近视性CNV的患者病历进行回顾性研究。排除患有其他眼科疾病的患者。对患者进行至少2年的随访。研究年龄与治疗期间视力变化及注射次数之间的相关性。
结果
患者年龄与接受的注射次数显著相关（Pearson相关系数=0.585，P=0.005）。此外，年龄与矫正远视力的改善也显著相关，矫正远视力改善定义为最终与初始LogMAR矫正远视力之差（Pearson相关系数=0.614，P=0.003）。
结论
年龄显著影响雷珠单抗治疗近视性CNV的视觉预后。在我们的研究中，年轻患者需要的玻璃体内注射次数更少，视力改善更显著。
Zotero 插件